Michael D. Saliba
Partner
New York
michael.saliba@lw.com
+1.212.906.4719
PRACTICES
- Capital Markets
INDUSTRIES
EDUCATION
- JD, Georgetown Law School, 2007
- BA, New York University, 2002
LANGUAGES SPOKEN
- English
PROFILE
Michael Saliba advises issuers, underwriters, sponsors, and investors on a range of complex domestic and cross-border capital markets transactions.
Drawing on his broad transactional experience and sector-specific knowledge, Michael helps clients successfully navigate a range of capital markets transactions, including:
- Acquisition financings
- High-yield and investment grade debt offerings
- Debt exchange offers, tender offers, and consent solicitations
- Initial public offerings and deSPAC transactions
- Project financings
- Registered and private equity financings
- Restructuring transactions
- Spin-off transactions
Michael also regularly counsels clients on a variety of corporate and securities law matters as well as high yield debt covenant and debt structuring analyses.
EXPERIENCE
Michael's experience includes advising:
Debt Offerings
- Aircastle Limited in multiple offerings of senior notes and in its inaugural preferred stock offering*
- HC2 in its US$330 million high yield offering of senior secured notes*
- Jefferies in the US$400 million high yield offering of senior secured notes by StoneMor*
- NCR in multiple high yield offerings of senior notes*
- R.R. Donnelley & Sons in its US$400 million high yield offering of senior secured notes*
- Stryker in its €2.4 billion offering of senior notes*
Initial Public Offerings and deSPAC Transactions
- Fortress Investment Group in the initial public offering of Brightline Holdings*
- NextGen Acquisition Corporation in its merger with Xos*
Liability Management Transactions
- Baxter International in its debt-for-equity exchanges and equity-for-equity exchange offer in connection with its spin-off of Baxalta*
Restructurings
- ADVANZ Pharma in its restructuring and recapitalization transactions*
- Highbridge Capital Management in the restructuring and refinancing transactions by Pernix Therapeutics*
- iPayment Holdings and iPayment in their units and US$400 million senior notes offerings and later restructuring*
*Matter handed prior to joining Latham